ArticleDiabetes/metabolism research and reviews2026
Evaluation of Urine Exosome Lecithin Cholesterol Acyltransferase as a Biomarker for Diabetes Diagnosis and Dyslipidemia.
Article in Diabetes/metabolism research and reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
aimsGiven the necessity for diabetes monitoring, investigating the expression of lipid metabolism-related proteins may provide valuable insights for disease surveillance and mechanistic elucidation. MATERIALS AND
methodsLC-MS/MS was used to analyse the expression of lipid metabolism-related proteins in urine exosomes. Biomarkers were screened and their clinical significance was evaluated. Insulin-resistant hepatocytes and diabetic mouse models were established to validate and explore the underlying mechanisms.
resultsLogistic regression analysis revealed that elevated triglyceride (TG) and reduced high-density lipoprotein cholesterol (HDL-C) were independent risk factors for diabetes. In normal controls and those with prediabetes, females had higher total cholesterol (TC) and HDL-C but lower TG compared to males, whereas no gender differences were observed in the diabetic group. 29 lipid metabolism-related proteins were screened by proteomics, among which lecithin cholesterol acyltransferase (LCAT) was the target protein. Disordered lipid metabolism and upregulation of LCAT were observed in diabetic patients, insulin-resistant cells, and diabetic mice. The liver may be a key organ of early diabetic injury, as evidenced by disorganised hepatocyte arrangement and compensatory LCAT production during the prediabetic stage. As the disease progresses to diabetes, hepatic steatosis significantly worsens, accompanied by elevation of serum and urine LCAT. Urine exosome LCAT not only holds diagnostic value but also exhibits distinctive dynamic changes: an early rise in diabetes followed by a decline during periods of poor glycaemic control (HbA1c ≥ 8% or FBG > 7.8 mmol/L).
conclusionsLCAT, a critical regulator of lipid metabolism, could serve as a novel biomarker for detection and monitoring of diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.